APVO436 is an optimized, next generation ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several hematological malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, hairy cell leukemia, myelodysplastic syndrome, and blastic plasmacytoid dendritic cell neoplasm.

Aptevo has filed an Investigational New Drug Application and expects to begin Phase 1 development of APVO436 in patients with acute myeloid leukemia (AML) in the fourth quarter of 2018.